HK1146726A1 - 成纖維細胞生長因子受體 表達的反義調節 - Google Patents

成纖維細胞生長因子受體 表達的反義調節

Info

Publication number
HK1146726A1
HK1146726A1 HK11100334.2A HK11100334A HK1146726A1 HK 1146726 A1 HK1146726 A1 HK 1146726A1 HK 11100334 A HK11100334 A HK 11100334A HK 1146726 A1 HK1146726 A1 HK 1146726A1
Authority
HK
Hong Kong
Prior art keywords
growth factor
factor receptor
fibroblast growth
receptor expression
antisense modulation
Prior art date
Application number
HK11100334.2A
Other languages
English (en)
Inventor
Sanjay Bhanot
Ravi Jain
Xing-Xian Yu
Susan M Freier
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of HK1146726A1 publication Critical patent/HK1146726A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK11100334.2A 2007-10-01 2011-01-14 成纖維細胞生長因子受體 表達的反義調節 HK1146726A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97678207P 2007-10-01 2007-10-01
PCT/US2008/078497 WO2009046141A2 (en) 2007-10-01 2008-10-01 Antisense modulation of fibroblast growth factor receptor 4 expression

Publications (1)

Publication Number Publication Date
HK1146726A1 true HK1146726A1 (zh) 2011-07-08

Family

ID=40526946

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11100334.2A HK1146726A1 (zh) 2007-10-01 2011-01-14 成纖維細胞生長因子受體 表達的反義調節

Country Status (14)

Country Link
US (2) US8486904B2 (zh)
EP (1) EP2215102B1 (zh)
JP (1) JP5792955B2 (zh)
KR (1) KR101660989B1 (zh)
CN (1) CN101883777B (zh)
AU (1) AU2008308691B2 (zh)
BR (1) BRPI0817527A2 (zh)
CA (1) CA2701128A1 (zh)
HK (1) HK1146726A1 (zh)
IL (1) IL204796A (zh)
MX (1) MX2010003606A (zh)
NZ (1) NZ584827A (zh)
RU (1) RU2501803C2 (zh)
WO (1) WO2009046141A2 (zh)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101660989B1 (ko) 2007-10-01 2016-09-28 아이오니스 파마수티컬즈, 인코포레이티드 섬유아세포 성장 인자 수용체 4 발현의 안티센스 조절
JP5645840B2 (ja) 2008-12-02 2014-12-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ リン原子修飾核酸の合成方法
CA2758927A1 (en) * 2009-04-15 2010-10-21 Isis Pharmaceuticals, Inc. Modulation of inflammatory responses by factor xi
JP5998326B2 (ja) 2009-07-06 2016-09-28 ウェイブ ライフ サイエンス リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 新規核酸プロドラッグおよびその使用方法
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
AU2012242642A1 (en) 2011-04-13 2013-05-02 Ionis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
CN103597074A (zh) * 2011-06-16 2014-02-19 Isis制药公司 成纤维细胞生长因子受体4表达的反义调节
MX347361B (es) 2011-07-19 2017-04-12 Wave Life Sciences Ltd Metodos para la sintesis de acidos nucleicos funcionalizados.
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102337247B (zh) * 2011-09-13 2013-07-10 西安交通大学 一种fgfr4高表达的重组hek293细胞及其应用
EA036592B1 (ru) 2012-06-13 2020-11-26 Инсайт Холдингс Корпорейшн Замещенные трициклические соединения как ингибиторы fgfr
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
WO2014010718A1 (ja) 2012-07-13 2014-01-16 株式会社新日本科学 キラル核酸アジュバント
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
AR092982A1 (es) * 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
RU2015119411A (ru) 2012-11-15 2017-01-10 Рош Инновейшен Сентер Копенгаген А/С Конъюгаты антисмысловых соединений, направленные на аполипопротеин в
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US20150368642A1 (en) 2013-01-30 2015-12-24 Hoffmann-La Roche Inc. Lna oligonucleotide carbohydrate conjugates
WO2014172644A2 (en) 2013-04-19 2014-10-23 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
RU2019110030A (ru) 2013-05-01 2019-05-06 Ионис Фармасьютикалз, Инк. Композиции и способы
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
SG10201912897UA (en) 2014-01-16 2020-02-27 Wave Life Sciences Ltd Chiral design
IL247600B (en) 2014-03-19 2022-06-01 Ionis Pharmaceuticals Inc Preparations for the modulation of ataxin 2 expression
US10006027B2 (en) 2014-03-19 2018-06-26 Ionis Pharmaceuticals, Inc. Methods for modulating Ataxin 2 expression
WO2015168618A2 (en) 2014-05-01 2015-11-05 Isis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
WO2015179693A1 (en) 2014-05-22 2015-11-26 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2991894A1 (en) * 2015-07-10 2017-01-19 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (dgat2)
KR20190065341A (ko) 2016-10-06 2019-06-11 아이오니스 파마수티컬즈, 인코포레이티드 올리고머 화합물들의 접합 방법
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
CA3099287A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
EP3826645A4 (en) 2018-07-25 2023-05-17 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR REDUCING ATXN2 EXPRESSION
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN112759593A (zh) 2019-11-01 2021-05-07 北京伯汇生物技术有限公司 桥环并醛基吡啶衍生物及其应用
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0420081A1 (en) 1989-09-26 1991-04-03 Takeda Chemical Industries, Ltd. Monoclonal antibody against an acidic FGF protein, its production and use
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US20040006005A1 (en) * 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
AU6080194A (en) * 1992-12-31 1994-08-15 Texas Biotechnology Corporation Antisense molecules directed against a fibroflast growth factor receptor gene family
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US20050053976A1 (en) * 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
WO2001018210A1 (en) 1999-09-08 2001-03-15 Genentech, Inc. Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
EP1071429B1 (en) 1998-04-17 2002-01-30 Trustees Of Tufts College Map kinase inhibitors in the treatment of disorders caused by tnf-alpha induced lipolysis
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
US6153432A (en) 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
US6136603A (en) * 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
BR0010482A (pt) 1999-05-21 2002-04-23 Bristol Myers Squibb Co Inibidores pirrolotriazìnicos de cinases
WO2001049849A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf11
US6261840B1 (en) * 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US6159734A (en) * 2000-01-18 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of peroxisome proliferator-activated receptor gamma expression
CA2403572A1 (en) 2000-03-22 2001-09-27 Amgen Inc. Fibroblast growth factor receptor-like molecules and uses thereof
WO2001072957A2 (en) 2000-03-31 2001-10-04 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
CA2408701A1 (en) 2000-05-12 2001-11-22 University Of Utah Research Foundation Compositions and methods for tissue dedifferentiation and regeneration
EP1202065A1 (en) 2000-10-25 2002-05-02 Aventis Pharma S.A. Net, a transcription factor of the TCF family, as regulator of angiogenic expression.
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
DE10152147A1 (de) 2001-10-25 2003-05-15 Chemogenix Gmbh Verfahren zum Aufbringen von Nukleosiden und/oder Nukleotiden auf funktionalisierten Oberflächen sowie Verfahren zur Bestimmung von Kopplungsausbeuten bei der Synthese von Nukleotiden
EP1441725A1 (en) 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
US7655397B2 (en) * 2002-04-25 2010-02-02 The United States Of America As Represented By The Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
CA2486183C (en) 2002-05-23 2012-01-10 Cytopia Pty Ltd. Protein kinase inhibitors
TW200401638A (en) 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
CA2490261A1 (en) * 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor
KR101016250B1 (ko) 2002-07-08 2011-02-25 코닌클리즈케 필립스 일렉트로닉스 엔.브이. 반사형 디스플레이 및 이를 포함하는 휴대형 장치
CA2504044A1 (en) 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
EP1560931B1 (en) * 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
US7803781B2 (en) * 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20050048494A1 (en) * 2003-08-28 2005-03-03 Yixin Wang Colorectal cancer prognostics
WO2005037235A2 (en) 2003-10-16 2005-04-28 Imclone Systems Incorporated Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
AU2005213484A1 (en) * 2004-02-05 2005-08-25 Intradigm Corporation RNAi therapeutics for treatment of eye neovascularization diseases
EP1713819A4 (en) * 2004-02-05 2007-11-14 Intradigm Corp METHOD AND COMPOSITIONS FOR COMBINING RNAI THERAPEUTICS
US7374927B2 (en) * 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
AU2005245896A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
US20090036355A1 (en) * 2004-10-13 2009-02-05 Sanjay Bhanot Antisense Modulation of PTP1B Expression
US20090299640A1 (en) * 2005-11-23 2009-12-03 University Of Utah Research Foundation Methods and Compositions Involving Intrinsic Genes
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
US20100105134A1 (en) * 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2008109369A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
KR101660989B1 (ko) 2007-10-01 2016-09-28 아이오니스 파마수티컬즈, 인코포레이티드 섬유아세포 성장 인자 수용체 4 발현의 안티센스 조절

Also Published As

Publication number Publication date
WO2009046141A2 (en) 2009-04-09
KR20100081994A (ko) 2010-07-15
EP2215102B1 (en) 2016-02-17
WO2009046141A3 (en) 2009-05-28
JP5792955B2 (ja) 2015-10-14
KR101660989B1 (ko) 2016-09-28
CN101883777B (zh) 2015-03-25
EP2215102A4 (en) 2012-04-11
US20140080892A1 (en) 2014-03-20
RU2501803C2 (ru) 2013-12-20
AU2008308691B2 (en) 2013-11-07
US8486904B2 (en) 2013-07-16
US20100292140A1 (en) 2010-11-18
RU2010116994A (ru) 2013-01-20
IL204796A (en) 2014-04-30
US8895529B2 (en) 2014-11-25
AU2008308691A1 (en) 2009-04-09
BRPI0817527A2 (pt) 2017-05-02
IL204796A0 (en) 2010-11-30
JP2010539950A (ja) 2010-12-24
CA2701128A1 (en) 2009-04-09
MX2010003606A (es) 2010-07-02
NZ584827A (en) 2012-10-26
CN101883777A (zh) 2010-11-10
EP2215102A2 (en) 2010-08-11

Similar Documents

Publication Publication Date Title
HK1146726A1 (zh) 成纖維細胞生長因子受體 表達的反義調節
PL2292187T3 (pl) Endoproteza rosnąca
EP2242437A4 (en) PROSTHESIS OF FACETARY FASTENING
EP2309951A4 (en) MEMBER PROSTHESIS
EP2259753A4 (en) JOINT IMPLANT WITH ADJUSTED EDGE
IL229822A0 (en) Methods for monitoring the modulation of the kinase activity of the fibroblast growth factor receptor and uses of these methods
EP2493404A4 (en) IMPLANT FOR BAG HOLDING WITH ADJUSTMENT SADDLE
EP2385810A4 (en) ILIAC CHANNEL PROSTHESIS
EP2254519A4 (en) KNEE TOTAL PROSTHESIS
PL2358309T3 (pl) Implant o strukturze kratownicowej
EP2378983A4 (en) IMPLANTABLE PROSTHESIS
EP2231061A4 (en) Implantable prosthesis
ZA201100697B (en) Orthopedic prosthesis
PL2274023T3 (pl) Protetyczne implanty podobne do kości
EP2721156A4 (en) ANTISENSE MODULATION OF FIBROBLASTIC GROWTH FACTOR RECEPTOR 4 RECEPTOR EXPRESSION
GB2445869B (en) Tendon-integrated prosthesis
EP2349108A4 (en) ORTHOPEDIC IMPLANT WITH SPATIALLY VARIANT POROSITY
EP2437630A4 (en) CERAMIC APPLICATOR FOR COSMETIC PRODUCT
GB0803679D0 (en) Prosthesis
EP2431031A4 (en) COMPOSITION FOR PREVENTING HAIR LOSS AND STIMULATING HAIR GROWTH
EP2454369A4 (en) MODULATION OF FACTOR 7 EXPRESSION
EP2310035A4 (en) FIBROBLAST GROWTH FACTOR (FGF) ANALOGUE AND ITS USES
HK1137482A1 (en) Improvement of cell growth
GB0816577D0 (en) Growth factor
GB0803676D0 (en) Prosthesis

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200927